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PharmacokineticsThe liquid chromatography–tandem mass spectrometric assay method for the simultaneous
determination of rosuvastatin and amlodipine in human plasma using deuterated analogs as
internal standards has been developed and validated. The analytes were extracted from
100 lL aliquots of human plasma via liquid–liquid extraction using a mixture of ethyl acetate
and n-hexane (80:20, v/v) as an extraction solvent. The optimized mobile phase was composed
of 0.1% formic acid in 5 mM ammonium acetate, methanol, and acetonitrile (20:20:60, v/v/v)
and delivered at a ﬂow rate of 0.75 mL/min. The calibration curve obtained was linear
(R2P 0.999) over the concentration range of 0.52–51.77 ng/mL for rosuvastatin and
0.10–10.07 ng/mL for amlodipine. A sample turnover rate of less than 2.5 min makes it an
attractive procedure in high-throughput bioanalysis of rosuvastatin and amlodipine. The
present method was found to be applicable to clinical studies and the results were authenticated
by incurred sample reanalysis.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
Hypertension and hyperlipidaemia are major risk factors for
the development of atherosclerosis and its associated condi-
tions such as coronary heart disease, ischemic cerebrovascular
disease, and peripheral vascular disease. Calcium antagonists
have been used for decades as antihypertensive agents.
On the other hand, 3-hydroxy-3-methylglutaryl coenzyme A
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sively used for the treatment of hyperlipidaemia because of
their potent lipid lowering properties [1–3].
Rosuvastatin, a synthetic statin, was developed for the
treatment of hyperlipidaemia [4,5]. The dose dependent peak
plasma concentration (Cmax) reached 3–5 h after oral adminis-
tration of a 10- to 80-mg dose [6–8]. Amlodipine, a calcium
antagonist, is prescribed for the treatment of hypertension
and angina pectoris. It has a long elimination half-life and
large volume of distribution. Low plasma concentrations (ng
or pg) were reported after oral administration of amlodipine.
The combination of rosuvastatin and amlodipine exerts more
beneﬁcial effects on cardiomyocyte hypertrophy and ﬁbrosis
[9,10]. Compared with the co-administration of each drug,
the convenience of a ﬁxed dose combination (FDC) tablet
has the potential outcome to improve patient adherence and
the management of cardiovascular risk, thereby improving
clinical outcomes.
Many liquid chromatography–tandem mass spectrometric
(LC/MS/MS) methods have been reported for the determina-
tion of rosuvastatin [11–18] individually or in combination with
other drugs in biological samples. The major disadvantages of
these methods include, less sensitivity [11], more sample volume
(>0.25 mL) [11,13,14,19], longer chromatographic run time
(>4 min) [11–18], complex with derivatization and expensive
automated extraction procedure [13,18], and narrow linearity
range not suitable for bioequivalence/pharmacokinetic applica-
tion in humans at higher dose (0.1–30 ng/mL) [13,14]. Simi-
larly, numerous LC/MS/MS methods are described in the
literature to determine amlodipine in different biological ﬂuids
[19–31]. Among the applied methods, either the chromato-
graphic run time was long (>4 min) [19,20,22,24,25,30,31],
the plasma volume was high (>0.25 mL) [19,21–25,30] or the
method was insensitive for bioequivalence/pharmacokinetic
application [20,23,25,27,30,31].
Some methods [15,21,26–29] which can be applied for quan-
titation of one drug in biological ﬂuids selectively and sensi-
tively, cannot be applied satisfactorily for simultaneous
determination of rosuvastatin and amlodipine. To investigate
the safety and tolerability of rosuvastatin and amlodipine ﬁxed
dose combination (FDCs) and/or for comparative bioavailabil-
ity and bioequivalence studies of rosuvastatin associated with
amlodipine, it is necessary to perform the quantitation of rosu-
vastatin and amlodipine simultaneously. An effective bio-ana-
lytical method should gratify in terms of sensitivity, efﬁcient
extraction process, rapid chromatography and speciﬁc. To
our knowledge, no LC/MS/MS method has been reported for
the simultaneous determination of amlodipine and rosuvastatin
in human plasma. The present work describes a simple, selec-
tive and sensitive method, which employs liquid–liquid extrac-
tion (LLE) technique for sample preparation and liquid
chromatography with electrospray ionization–tandem mass
spectrometry for simultaneous quantitation of rosuvastatin
and amlodipine in human plasma. The method uses isotope
labeled compound rosuvastatin d6 and amlodipine d4 maleate
as internal standards (IS) for the quantitation of rosuvastatin
and amlodipine, respectively to avoid the potential matrix
effect related problems and variability in recovery between
analyte and IS. The suggested assay was applied to a clinical
study in humans following oral administration of rosuvastatin
and amlodipine. Furthermore, assay reproducibility is demon-
strated by conducting incurred sample reanalysis (ISR).Experimental
Reagents and chemicals
Reference standards of amlodipine besylate (purity 99.95%),
amlodipine d4 maleate (IS1; purity 99.35%) and rosuvastatin
d6 sodium salt (IS2; purity 99.87%) were purchased from
Vivan Life Sciences Ltd. (Mumbai, India), while rosuvastatin
calcium (purity 95.40%) was from Hetero Drugs Ltd. (Hyder-
abad, India). Water used for the LC/MS/MS analysis was pre-
pared from Milli Q water puriﬁcation system procured from
Millipore (Bangalore, India). HPLC grade acetonitrile and
methanol were purchased from J.T Baker (Phillipsburg,
USA); while ethyl acetate and n-hexane were from Merck
Ltd. (Mumbai, India). Analytical grade formic acid and
ammonium acetate were also purchased from Merck
(Mumbai, India). The control human plasma sample was pro-
cured from Deccan’s Pathological Labs (Hyderabad, India).
Preparation of stock and working solutions
Primary stock solutions (1 mg/mL) of rosuvastatin, amlodip-
ine, IS1, and IS2 were prepared in methanol and these stocks
were stored at 2–8 C. Working solutions were prepared in a
mixture of acetonitrile and water (50:50, v/v; diluent) for the
purpose of plotting the calibration curve (CC) standards.
Another set of working solutions were prepared in appropriate
concentrations (using the same diluent) for quality
control (QC) samples. A combined working solution for IS1
(500 ng/mL) and IS2 (50 ng/mL) was also prepared in diluent.Preparation of calibration curve standards and quality control
samples
Calibration samples were prepared by spiking 950 lL of con-
trol human plasma with the appropriate working standard
solution of the each analyte (50 lL combined dilution of rosu-
vastatin and amlodipine). Calibration curve (CC) standards of
analytes in blank plasma were prepared by spiking with an
appropriate volume of the working solutions, giving ﬁnal con-
centrations of 0.52, 1.04, 2.59, 5.19, 10.37, 20.75, 31.06, 41.41,
and 51.77 ng/mL for rosuvastatin and 0.10, 0.20, 0.51, 1.01,
2.02, 4.04, 6.04, 8.06, and 10.07 ng/mL for amlodipine. The
CC samples were analyzed along with the quality control
(QC) samples for each batch of plasma samples. The QC sam-
ples were prepared at ﬁve different concentration levels of 0.52
(lower limit of quantiﬁcation, LLOQ), 1.49 (low quality con-
trol, LQC), 6.19 (middle quality control, MQC-1), 25.78
(MQC-2) and 46.03 (high quality control, HQC) ng/mL for
rosuvastatin and 0.10 (LLOQ), 0.29 (LQC), 1.20 (MQC-1),
5.02 (MQC-2) and 8.96 (HQC) ng/mL for amlodipine. All
the prepared plasma samples were stored at 70 ± 10 C.
Sample processing
All frozen subject samples, calibration standards and quality
control samples were thawed and allowed to equilibrate at
room temperature prior to analysis. The samples were vor-
texed for 10 s prior to spiking. A 100 lL aliquot of human
plasma sample was mixed with 25 lL of the internal standard
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After vortexing for 15 s, a 4 mL of extraction solvent (ethyl
acetate and n-hexane, 80:20, v/v) was added using Dispensette
Organic (Brand GmbH, Wertheim, Germany). The sample was
shaken for 10 min using a reciprocating shaker (Scigenics Biotech,
Chennai, India) and then centrifuged for 5 min at 4000 rpm on
Megafuse 3SR (Heraeus, Germany). The clear organic layer
(3 mL) was transferred to a 5 mL glass test tube and evaporated
at 45 C under a gentle stream of nitrogen. The dried extract
was reconstituted with 250 lL of the mobile phase and a 20 lL ali-
quot of it was injected into the LC/MS/MS system.
Chromatographic conditions
An HPLC system (Shimadzu, Kyoto, Japan) consisting of a
Zorbax SB C18 column (50 · 4.6 mm, 3.5 lm; Agilent Technol-
ogies, Santa Clara, CA, USA), a binary LC-20AD prominence
pump and an autosampler (SIL-HTc), and a solvent degasser
(DGU-20A3) were used for the study. Aliquots of the pro-
cessed samples (20 lL) were injected into the column, which
was kept at ambient temperature (25 ± 5 C). An isocratic
mobile phase of a mixture of 0.1% formic acid in 5 mM
ammonium acetate, methanol and acetonitrile (20:20:60, v/v/
v) was delivered at a rate of 0.75 mL/min into the electrospray
ionization chamber of the mass spectrometer.
Mass spectrometry conditions
Quantitation was achieved with MS/MS detection in positive
ion mode for both the analytes and the internal standards
using an AB Sciex API-4000 mass spectrometer (Foster City,
CA, USA) equipped with a Turboionspray interface at
550 C. The ion spray voltage was set at 5500 V. The source
parameters viz. the nebulizer gas (GS1), auxiliary gas (GS2),
curtain gas (CUR) and collision gas (CAD) were set at 45,
40, 40 and 8 psi, respectively. The compound parameters viz.
the declustering potential (DP), collision energy (CE), entrance
potential (EP) and collision cell exit potential (CXP) were 110,
47, 10, 15 V for rosuvastatin, 35, 15, 10, 13 V for amlodipine,
46, 47, 10, 15 V for IS1 and 35, 15, 10, 13 V for IS2. Detection
of the ions was carried out in the multiple reaction monitoring
(MRM) mode by monitoring the transition pairs of m/z 482.1
precursor ion to the m/z 258.3 for rosuvastatin, m/z 409.4 pre-
cursor ion to the m/z 238.1 for amlodipine, m/z 488.1 precursor
ion to the m/z 264.2 for the IS1 and m/z 413.2 precursor ion to
the m/z 238.0 product ion for the IS2. Quadrupoles Q1 and Q3
were set on unit resolution. The analysis data obtained were
processed by Analyst software (version 1.6.1).
Method validation
A through method validation was carried out as per US FDA
and EMEA guidelines [32,33]. The parameters included carry
over, selectivity, speciﬁcity, sensitivity, matrix effect, linearity,
precision and accuracy, recovery, dilution integrity, stability
and run size evaluation.
Pharmacokinetic study design and incurred sample reanalysis
A single dose pharmacokinetic study was performed in healthy
South Indian male subjects (n= 12). The Ethics Committee(Samkshema Independent Ethics Committee, Hyderabad,
India) approved the protocol and the volunteers provided with
written informed consent. All the subjects were fasted for 12 h
before the drug formulation administration. Twelve healthy
male subjects with an age group of 20–40 years and body-mass
index (BMI) of P18.5 kg/m2 and 624.9 kg/m2, with body
weight not less than 50 kg were chosen for the study. They
were randomly assigned to two groups and took a single oral
dose of 40 mg rosuvastatin and 10 mg amlodipine tablets,
respectively. Blood samples were collected at 1, 2, 2.33, 2.67,
3, 3.33, 3.67, 4, 4.33, 4.67, 5, 5.33, 5.67, 6, 6.5, 7, 8, 10, 12,
24, 48, 72 and 96 h for rosuvastatin and 0.5, 1, 1.5, 2, 2.5, 3,
4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96 and 120 h for amlodipine
in K2 EDTA vacutainer (5 mL) collection tubes (BD, Frank-
lin, NJ, USA). A predose sample was also collected before
administration of each drug formulation. All the tubes were
centrifuged at 3200 rpm for 10 min and the supernatant
plasma was collected and stored at 70 ± 10 C till their
use. Plasma samples were spiked with the IS dilution and pro-
cessed as per the procedure described under sample processing.
WinNonlin Version 5.2 software was used to calculate main
pharmacokinetic parameters of rosuvastatin and amlodipine
by non-compartmental model. As per FDA [34] recommenda-
tions it is necessary to perform ISR using dosed subject sam-
ples. ISR is to verify the reliability and reproducibility of the
reported subject sample analyte concentrations. Hence, an
ISR was performed by selecting 2 samples from each subject
(a total of 12 samples for each analyte) near Cmax and the
elimination phase in the pharmacokinetic proﬁle of both the
drugs. The reanalyzed values were compared with the initial
values. The percent change deviation allowed is ±20% [35].Results and Discussion
Optimization of chromatographic conditions
It was difﬁcult to set chromatographic conditions that
produced sharp peak shape and adequate response for rosu-
vastatin and amlodipine due to their different physicochemical
properties. To develop a selective and sensitive analytical
method in biological samples requires the judicious selection
of column, mobile phase and organic solvent. These parame-
ters should be suitably monitored to produce the better resolu-
tion from endogenous components which in turn affect
sensitivity and reproducibility of the analytical method. Once
the above mentioned parameters were optimized the ﬂow rate,
column temperature and buffer type and concentration can be
altered for optimal response. Separation was attempted using
organic solvents such as methanol and acetonitrile in different
volume ratios with buffers such as ammonium formate, ammo-
nium acetate (2–15 mM) as well as acid additives such as acetic
acid and formic acid (0.1–0.4%) in varying strength on differ-
ent columns such as C8 and C18 of different makes (Hypurity
advance 75 · 4.6, 5 lm; Zorbax SB C18, 50 · 4.6, 3.5 lm;
Kromasil 100-5C18, 100 · 4.6, 5 lm; Ace 3 C18 150 · 4.6,
3 lm; Alltima HP C18 50 · 4.6, 3 lm; Zorbax XDB-phenyl
75 · 4.6, 3.5 lm; Discovery HS C18 50 mm · 4.6 mm, 5 lm).
It was observed that 0.1% formic acid in 5 mM ammonium
acetate, methanol and acetonitrile (20:20:60, v/v/v) as the
mobile phase was most appropriate to give best sensitivity,
efﬁciency and peak shape for both analytes and the internal
934 A. Narapusetti et al.standards. Among the various chromatographic columns
tested for their suitability Zorbax SB C18, 50 · 4.6 mm,
3.5 lm column gave good peak shape and response even
at lowest concentration level for both the analytes. In
addition, the effect of ﬂow rate was also studied from
0.25 to 1.0 mL/min, which was also responsible for accept-
able chromatographic peak shape and short run time and
ﬁnally was set at 0.75 mL/min. The retention time of
rosuvastatin, amlodipine, IS1 and IS2 (1.3, 1.7, 1.3 and
1.7 min, respectively) was low enough allowing a small run
time of 2.5 min.Fig. 1 Typical MRM chromatograms of rosuvastatin (left panel) an
sample along with IS (B), and 3 h subject plasma sample (C), after the
The sample concentration was determined to be 28.28 ng/mL.Mass spectrometry
The present study was carried out using ESI as the ionization
source. The mass parameters were optimized using 100 ng/mL
of tuning solution of analytes in positive and negative ioniza-
tion modes. However, the response observed was much higher
in positive ionization mode for the analytes compared to the
negative mode due to their basic nature. To develop sensitive
and selective assay method for the quantiﬁcation of rosuvast-
atin and amlodipine different options were evaluated to
optimize detection and chromatography parameters. Thed IS (right panel) in human plasma spiked with IS (A), a LLOQ
administration of a 40 mg oral single dose of rosuvastatin tablet.
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parameters were suitably optimized to get better sensitivity
and selectivity. As earlier publications have discussed the
details of fragmentation patterns of rosuvastatin [12] and
amlodipine [22], we are not presenting the data pertaining to
this. LC-MRM technique was used for the quantiﬁcation of
analytes since it provides sensitivity and selectivity.
Optimization of sample extraction procedure
Single step extraction of rosuvastatin and amlodipine from
plasma was difﬁcult due to their physiochemical propertiesFig. 2 Typical MRM chromatograms of amlodipine (left panel) an
sample along with IS (B), and 3 h subject plasma sample (C), after the a
sample concentration was determined to be 1.51 ng/mL.and polarities. Initially, solid phase extraction (SPE) was tried
with Oasis HLB, Starata polymeric sorbent, Bond Elut Plexa
and Orpheus C18 extraction cartridges with/without acidic buf-
fer addition to obtain the clean sample and to remove the
interference from endogenous components. But, the recovery
results obtained for amlodipine were in-consistent at different
QC levels. Thus, LLE was carried out using solvents like
dichloromethane, ethyl acetate, hexane, diethyl ether, chloro-
form and methyl tert-butyl ether (MTBE), alone and in com-
bination with and without addition of acidic/basic buffers.
But although MTBE in combination with dichloromethane
gave promising results, the recovery was not consistent ford IS (right panel) in human plasma spiked with IS (A), a LLOQ
dministration of a 10 mg oral single dose of amlodipine tablet. The
936 A. Narapusetti et al.amlodipine at LQC level. Poor recovery results were obtained
with diethyl ether and dichloromethane. Finally promising
results were obtained with ethyl acetate and n-hexane (80:20,
v/v), which can produce a clean chromatogram for a blank
sample and yields the highest recovery for the analyte from
the plasma. Stable labeled isotope standards of the analyte
as an internal standard is suggested for bioanalytical assays
to increase assay precision and limit variable recovery between
analyte and the IS [36]. Hence, rosuvastatin d6 and amlodipineTable 1 Intra-day and inter-day precision and accuracy data for ro
QC Intra-day precision and ac
(n= 12; 6 from each ba
Analyte Concentration
spiked (ng/mL)
Concentration found
(mean; ng/mL)
Precision
(%)
Rosuvastatin 0.52 0.51 ± 0.01 2.82
1.49 1.47 ± 0.02 1.35
6.19 6.03 ± 0.09 1.51
25.78 25.45 ± 0.35 1.36
46.03 44.67 ± 0.40 0.89
Amlodipine 0.10 0.10 ± 0.00 2.22
0.29 0.29 ± 0.01 2.19
1.20 1.20 ± 0.02 1.31
5.02 5.01 ± 0.06 1.19
8.96 8.87 ± 0.10 1.18
Table 2 Stability data for rosuvastatin and amlodipine (n= 6).
Analyte Stability test QC (spiked concentration (ng/mL)
Rosuvastatin Processa 1.49
46.03
Processb 1.49
46.03
Bench topc 1.49
46.03
FTd 1.49
46.03
Reinjectione 1.49
46.03
Long-termf 1.49
46.03
Amlodipine Processa 0.29
8.96
Processb 0.29
8.96
Bench topc 0.29
8.96
FTd 0.29
8.96
Reinjectione 0.29
8.96
Long-termf 0.29
8.96
a After 80 h in autosampler at 10 C.
b After 75 h in refrigerator at 2–8 C.
c After 12 h at room temperature.
d After 5 freeze and thaw cycles.
e After 42 h of Reinjection.
f At 70 C for 68 days.d4 maleate were selected for the quantiﬁcation of rosuvastatin
and amlodipine, respectively.
Selectivity and chromatography
The degree of interference by endogenous plasma components
with the analytes and the internal standards was assessed by
inspection of chromatograms derived from processed blank
plasma sample. As shown in Figs. 1 and 2, no signiﬁcant directsuvastatin and amlodipine.
curacy
tch)
Inter-day precision and accuracy
(n= 30; 6 from each batch)
Accuracy
(%)
Concentration found
(mean; ng/mL)
Precision
(%)
Accuracy
(%)
97.69 0.52 ± 0.02 4.67 100.50
98.79 1.50 ± 0.03 2.11 100.68
97.41 6.15 ± 0.13 2.19 99.41
98.73 25.88 ± 0.47 1.81 100.41
97.05 45.26 ± 0.61 1.34 98.32
99.59 0.10 ± 0.00 2.87 100.40
100.55 0.30 ± 0.01 2.42 102.45
99.47 1.22 ± 0.03 2.46 101.65
99.80 5.12 ± 0.11 2.23 102.01
99.00 9.00 ± 0.15 1.69 100.48
Mean ± SD (ng/mL) Accuracy/Stability (%) Precision (%)
1.53 ± 0.02 102.77 1.14
45.77 ± 0.39 99.44 0.85
1.52 ± 0.01 102.56 0.95
46.11 ± 0.34 100.19 0.73
1.53 ± 0.02 103.10 1.22
46.08 ± 0.44 100.12 0.95
1.52 ± 0.02 102.56 1.48
45.71 ± 0.49 99.31 1.07
1.48 ± 0.02 99.93 1.56
44.65 ± 0.39 97.01 0.87
1.52 ± 0.02 102.05 1.13
46.12 ± 0.23 100.20 0.50
0.30 ± 0.01 104.90 3.21
9.11 ± 0.27 101.71 2.91
0.30 ± 0.00 104.15 1.63
9.31 ± 0.10 103.91 1.11
0.30 ± 0.01 105.31 3.32
9.01 ± 0.35 100.58 3.91
0.31 ± 0.01 105.54 4.81
9.28 ± 0.15 103.61 1.66
0.30 ± 0.01 103.06 1.90
8.89 ± 0.05 99.26 0.53
0.31 ± 0.01 106.23 4.21
9.08 ± 0.24 101.38 2.59
Fig. 3 Mean plasma concentration-time proﬁle of rosuvastatin
(A), amlodipine (B), in human plasma following oral dosing of
rosuvastatin (40 mg) and amlodipine (10 mg) tablet to healthy
volunteers (n= 6).
Table 3 Pharmacokinetic parameters of rosuvastatin and
amlodipine (n= 6, Mean ± SD).
Parameter Rosuvastatin Amlodipine
Cmax (ng/mL) 39.32 ± 5.25 3.68 ± 0.46
tmax (h) 3.78 ± 1.38 5.83 ± 0.41
AUC0–t (ng h/mL) 429.26 ± 224.35 141.88 ± 10.99
AUC0–inf (ng h/mL) 431.64 ± 225.48 160.72 ± 14.91
t1/2 (h) 12.68 ± 3.53 38.80 ± 8.78
Kel (h1) 0.06 ± 0.01 0.02 ± 0.00
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endogenous substances in drug-free plasma at the retention
time of the analytes. Also, no signiﬁcant interferences were
found from both the internal standards to the MRM channel
of the analytes. Similarly, no interference was observed from
over-the-counter (OTC) drugs such as paracetamol, nicotine,
pantoprazole, ibuprofen, caffeine, diphenhydramine, dicyclo-
mine and pseudoephedrine (data not shown).
Sensitivity
The lowest limit of reliable quantiﬁcation (LLOQ) for the
rosuvastatin and amlodipine was set at the concentration of
0.52 ng/mL and 0.10 ng/mL, respectively. At this concentra-
tion, the precision and accuracy results were found to be
16.69% and 110.15% and 12.53% and 110.07% for rosuvast-
atin and amlodipine, respectively.
Matrix effect
Matrix effect experiment was conducted in six different sources
of plasma lots at LQC and HQC level. The precision and
accuracy for rosuvastatin at LQC concentration were found
to be 1.24% and 110.73%, and at HQC level they were
1.32% and 92.13%, respectively. Similarly, the precision and
accuracy for amlodipine at LQC concentration were found
to be 3.21% and 94.44%, and at HQC level they were
2.13% and 93.47%, respectively.
Also, the average matrix factor valve calculate as the
response of the post spiked sample/response of neat sample for
rosuvastatin at LQC and HQC concentration were 0.99 and
1.00, respectively and for amlodipine were 1.02 and 1.01, respec-
tively which indicated negligible suppression or enhancement.
Calibration curve and linearity
Five calibration curves generated for rosuvastatin and
amlodipine were linear over the concentration range of
0.52–51.77 ng/mL and 0.10–10.07 ng/mL with a determination
coefﬁcient (R2)P 0.9992 and 0.9994, respectively. The mean
linear equation obtained for rosuvastatin and amlodipine
was y= (0.034760 ± 0.001474)x+ (0.000714 ± 0.000631)
and y= (0.287600 ± 0.017530)x+ (0.001480 ± 0.001247),
respectively where y is the peak area ratio of the analyte/IS
and x the concentration of the analyte.
Precision and accuracy
The results for intra-day and inter-day precision and accuracy
in plasma quality control samples are summarized in Table 1.
These results are well within the acceptance limits [32,33].
Recovery and dilution integrity
The recoveries of analytes and the internal standards were
good and reproducible. The mean overall recoveries (with
the precision range) of rosuvastatin and amlodipine were
79.53 ± 3.68% (1.19–8.56%) and 76.85 ± 4.73% (1.36–
7.57%), respectively. Similarly, the mean recovery of the IS1
and IS2 was 80.35% and 79.28%, respectively.The upper concentration limits can be extended to 83.43 ng/
mL for rosuvastatin and 16.24 ng/mL for amlodipine by 1/2
and 1/4 dilutions with screened human blank plasma. The pre-
cision and accuracy for rosuvastatin at 1/2 dilution were found
to be 1.60% and 98.78%, and at 1/4 dilution they were 0.89%
and 99.49%, respectively. Similarly, the precision and accuracy
for amlodipine at LQC concentration were found to be 1.04%
and 100.01%, and at HQC level they were 1.42% and 99.33%,
respectively.
Stability studies
In various stability experiments carried out namely bench
top stability (12 h), autosampler stability (80 h), repeated
freeze–thaw cycles (5 cycles), reinjection stability (42 h), wet
938 A. Narapusetti et al.extract stability (75 h at 2–8 C) and long-term stability at
70 C for 68 days the mean% nominal values of the analytes
were found to be within ±15% of the predicted concentrations
for the analytes at their LQC and HQC levels (Table 2). Thus,
the results were found to be within the acceptable limits during
the entire validation.
Stock solutions of rosuvastatin, amlodipine and internal
standards were found to be stable for 8 days at 2–8 C in
refrigerator. The percentage stability (with the precision range)
of rosuvastatin, amlodipine, IS1 and IS2 was 101.04%
(1.21–1.48%), 99.95% (1.42–2.36%), 99.93% (1.14–1.34%)
and 98.32% (1.20–2.17%), respectively.
Run size evaluation
Run size evaluation was carried out to assess the integrity of
the samples analyzed in a long run during study sample anal-
ysis. Thirty sets of each of LQC, MQC1, MQC2 and HQC
samples stored at 70 ± 10 C were processed and analyzed
for run size evaluation along with freshly spiked calibration
curve standards and quality control samples (Low, Middle
and High QC samples). 120 QC’s out of 120 QC’s of run size
evaluation and 24 QC’s out of 24 QC’s of freshly prepared
QCs for rosuvastatin were within 15% of their respective
nominal (theoretical) values. Similarly, 120 QC’s out of 120Table 4 Precision and accuracy data of quality control samples ana
Analyte QC concentration
spiked (ng/mL)
QC concen
found (mea
Rosuvastatin 1.50 1.44 ± 0.0
6.25 5.68 ± 0.1
26.03 24.58 ± 0.3
46.48 43.13 ± 0.9
Amlodipine 0.29 0.26 ± 0.0
1.21 1.12 ± 0.0
5.04 4.86 ± 0.0
8.99 8.60 ± 0.0
Table 5 Incurred samples re-analysis data of rosuvastatin and aml
Subject no. Rosuvastatin
Sampling
point (h)
Initial
conc. (ng/mL)
Re-assay
conc. (ng/mL)
Diﬀerencea (
1 5 35.06 33.16 5.56
1 24 3.21 3.37 4.68
2 4.33 35.34 38.25 7.89
2 24 4.87 5.40 10.24
3 4.67 29.39 27.36 7.15
3 12 4.26 4.52 5.87
4 3.67 36.55 33.45 8.87
4 24 2.30 2.01 13.39
5 5 42.40 43.23 1.94
5 48 3.10 2.92 6.02
6 4.33 36.45 38.92 6.57
6 12 2.92 3.22 9.72
a Expressed as [(initial conc.-re-assay conc.)/average] · 100%.QC’s of run size evaluation and 24 QC’s out of 24 QC’s of
freshly prepared QCs for amlodipine were within 15% of their
respective nominal (theoretical) values.
Pharmacokinetic study results
The sensitivity and selectivity of proposed method was veri-
ﬁed by applying real time subject sample analysis for a phar-
macokinetic study in humans (n= 12). The mean plasma
concentration vs time proﬁle of rosuvastatin and amlodipine
is shown in Fig. 3 and the corresponding pharmacokinetic
parameters are listed in Table 3. These pharmacokinetic
parameters are essential for therapeutic drug monitoring
studies and to study the relationship between drug dosage
regimens and concentration-time proﬁles. The precision and
accuracy results obtained for quality control samples
analyzed along with unknown subject plasma samples are
summarized in Table 4. These results indicate the reproduc-
ibility of the proposed method and reliability of the study
data.
The authenticity of the study data is demonstrated through
ISR. The differences in concentrations between the ISR and
the initial values for all the tested samples were less than
15% (Table 5), indicating good reproducibility of the present
method.lyzed along with unknown samples (n= 12; 6 from each batch).
tration
n; ng/mL)
Precision (%) Accuracy (%)
4 2.51 95.84
9 3.29 91.02
6 1.46 94.44
0 2.10 92.79
1 2.37 90.49
3 2.31 92.97
3 0.65 96.42
9 1.03 95.59
odipine.
Amlodipine
%) Sampling
point (h)
Initial
conc. (ng/mL)
Re-assay
conc. (ng/mL)
Diﬀerencea (%)
5 2.81 3.02 7.24
120 0.40 0.38 4.83
5 3.11 3.05 2.11
120 0.42 0.40 4.15
5 4.01 4.52 11.87
96 0.48 0.52 8.78
6 3.83 3.96 3.39
120 0.39 0.38 1.57
5 3.91 3.48 11.63
96 0.37 0.32 13.33
5 3.36 3.20 4.88
96 0.40 0.41 1.72
Simultaneous determination of rosuvastatin and amlodipine in human plasma 939Conclusions
In ultimate analysis it can be vouchsafed that, we have devel-
oped and validated a sensitive, selective and rapid LC/MS/MS
method in MRM mode for the simultaneous determination of
rosuvastatin and amlodipine in human plasma. This method
utilizes deuterated analogs as internal standards for the quan-
tiﬁcation to avoid the potential matrix effect related problems
and variability in recovery between analyte and IS. This is the
ﬁrst LC/MS/MS report for the simultaneous determination of
rosuvastatin and amlodipine in any of the biological matrices.
The proposed method is rapid with the chromatographic run
time of 2.5 min and suitable for high-throughput bioanalysis
of rosuvastatin and amlodipine simultaneously. Moreover,
the method showed suitability for clinical studies in humans.
In addition, assay reproducibility is effectively proved by
incurred sample reanalysis.Conﬂict of Interest
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